Breast Cancer Advisor: O'Regan - Cancer Therapy Advisor

Breast Cancer Advisor: O’Regan

Chapter 1

2016 SABCS: Clinical Insights for Breast Cancer Treatment

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses the research most likely to have a clinical impact presented at the 2016 San Antonio Breast Cancer Symposium (SABCS). Highlights include practice-changing findings from 3 trials of endocrine therapy, as well as a study about the use of everolimus with fulvestrant among patients with breast cancer.

Chapter 2

HER2-positive Metastatic and Triple-negative Cancer Treatments

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses emerging treatments for patients with HER2-positive, metastatic breast cancer, as well as those for triple-negative breast cancer. CDK inhibitors and everolimus are among the treatments used for patients with HER2-positive disease, though other drugs are being studied. Dr O’Regan also discusses current research on triple-negative cancer.

Chapter 3

Treatment-related Neuropathy and Breast Cancer Treatment

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses treatment-related neuropathy, which is a common adverse event among patients being treated for breast cancer. Dr O’Regan discusses options for mitigating this side effect, which can be caused by multiple frequently-used treatments.

Next hm-playlist in Breast Cancer